AcquisitionOther
TuHURA Biosciences acquired Kineta
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
TuHURA Biosciences -> Kineta
Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody to TuHURA immuno-oncology pipeline
Open source record (SEC) ↗